Company intelligence / Profile preview

858 Therapeutics

San Diego, California, United States8five8tx.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

858 Therapeutics has advanced its lead asset ETX‑19477—a potent and selective PARG inhibitor—into early-stage clinical trials for patients with advanced solid tumors. The company’s pipeline includes additional small molecule programs targeting novel nodes in cancer biology such as DNA repair mechanisms, innate immunity pathways, and RNA epigenetics. Recent financing rounds support ongoing clinical development.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ETX-19477

2 more assets in the full pipeline.

Request access →

Partnerships

OpenBench (collaboration on AI-driven small molecule drug discovery)

Beyond the preview

Go deeper on 858 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 858 Therapeutics.

Explore the full profile